LUN.CO - H. Lundbeck A/S

Copenhagen - Copenhagen Real Time Price. Currency in DKK
388.90
+4.90 (+1.28%)
At close: 4:59PM CEST
Stock chart is not supported by your current browser
Previous Close384.00
Open382.60
Bid388.00 x 0
Ask388.10 x 0
Day's Range382.00 - 388.90
52 Week Range212.70 - 413.20
Volume321,525
Avg. Volume409,485
Market Cap77.21B
Beta-0.90
PE Ratio (TTM)38.61
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2014-03-27
1y Target EstN/A
  • Is Teva Pharmaceutical (TEVA) Stock Worth the Risk?
    InvestorPlace21 days ago

    Is Teva Pharmaceutical (TEVA) Stock Worth the Risk?

    This highly levered, acquisition-focused growth story has come crashing down recently. It is eerily similar to when the highly-levered, acquisition-focused growth story of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) fell apart not too long ago. As we all know, VRX stock went bust and hasn’t recovered.

  • TheStreet.comlast month

    Teva's New CEO Brings This Secret Weapon

    The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.

  • Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
    Zackslast month

    Teva's New CEO Brings No Relief: Generic Drugmakers to Dump

    The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.

  • The Wall Street Journallast month

    Teva Appoints New Chief Executive After Months of Speculation

    Teva Pharmaceutical Industries named Kare Schultz as its new chief executive, ending months of speculation over who will lead the Israeli drug company.

  • Reuterslast month

    Israel's Teva Pharma appoints Lundbeck's Kare Schultz as CEO

    Teva Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new CEO and president on Monday, as it struggles with heavy debts and fierce competition for its generic drugs in the United States. Israel-based Teva's shares, which plunged after the company issued poor second-quarter results last month, rose 8 percent in early trade in Tel Aviv. Schultz will succeed Yitzhak Peterburg, who will continue as Teva's interim CEO until Schultz takes over.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LUN.CO earnings conference call or presentation 9-Aug-17 9:30am GMT

    Q2 2017 H Lundbeck A/S Earnings Call

  • How a drug company fighting depression and schizophrenia avoids 'ripoff' drug prices
    CNBC2 months ago

    How a drug company fighting depression and schizophrenia avoids 'ripoff' drug prices

    Lundbeck CEO Kare Schultz said he's not concerned about the president's tweet on "ripoff prices" aimed at the CEO of Merck.

  • Zacks3 months ago

    3 Large Cap Pharma Stocks to Buy Now

    The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare. This uncertainty has not led to weak trading, and large cap pharma stocks have been among some of the biggest gainers this year. Check out these three large cap pharma stocks to buy now!

  • Zacks4 months ago

    3 Large Cap Pharma Stocks to Buy Now

    Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!

  • 4 Large-Cap Drug Stocks To Buy Post Q1 Earnings
    Zacks5 months ago

    4 Large-Cap Drug Stocks To Buy Post Q1 Earnings

    Take a look at these four large-cap drug stocks including Merck (MRK) that look well-positioned post Q1 earnings.

  • Zacks5 months ago

    3 Large Cap Drug Stocks to Buy Now

    Our overall "Medical" sector is up about 7.78% year-to-date, which just edges out the gains of the S&P 500. Within this broad sector, one of the better performing industries has been what we call "Large Cap Pharmaceuticals."

  • Reuters5 months ago

    Lundbeck raises earnings guidance for the fourth time in 12 months

    Danish drugmaker Lundbeck raised its financial guidance for the fourth time in 12 months as sales of its anti-epileptic drug Sabril was not dented by copycat competition, as Lundbeck had expected, its chief executive said on Wedneday. * Lundbeck saw an increase in its net cash position of 3 billion crowns.

  • Bloomberg8 months ago

    Lundbeck Mulls Alzheimer's Combo Therapy in Wake of Drug Failure

    H. Lundbeck A/S is looking at ways to develop combination therapies for Alzheimer’s disease as the Danish brain-disorder specialist presses forward despite recent failures in late-stage patient trials....

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of LUN.CO earnings conference call or presentation 8-Feb-17 12:00pm GMT

    Q4 2016 H Lundbeck A/S Earnings Call

  • Reuters9 months ago

    Lundbeck bets on shark antibodies for new brain drugs

    Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix. The two companies said on Thursday that Lundbeck had made an undisclosed payment to Ossianix, which has labs in Britain, following experiments in mice showing the effective transfer of potential drugs across the blood-brain barrier. Getting modern large-molecule medicines across the barrier that protects the brain is a major challenge for drug developers.

  • Zacks11 months ago

    Cirrus Logic, Skechers, Valeo SA ADR, H Lundbeck AS and Quanta Services highlighted as Zacks Bull and Bear of the Day

    Cirrus Logic, Skechers, Valeo SA ADR, H Lundbeck AS and Quanta Services highlighted as Zacks Bull and Bear of the Day